Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
190 hedge funds and large institutions have $2.32B invested in Global Blood Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 65 increasing their positions, 62 reducing their positions, and 33 closing their positions.
237% more call options, than puts
Call options by funds: $78.3M | Put options by funds: $23.2M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
15% more capital invested
Capital invested by funds: $2.02B → $2.32B (+$295M)
3% more funds holding
Funds holding: 184 → 190 (+6)
5% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$44.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$41M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$26.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.5M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$27.9M |
| 2 |
PC
PointState Capital
New York
|
-$20.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.3M |
| 5 |
NC
Nexthera Capital
New York
|
-$12.3M |
GBT Hedge Fund Activity: Q4 2018 in Review
190 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2018, worth a combined $2.32B — up 15% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new GBT positions and 33 closed out — a net gain of 9 holders — while 65 added to existing stakes and 62 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $44.2M. The largest seller was Janus Henderson Group, cutting an estimated $27.9M.
- 190 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2018, up from 184 in Q3 2018.
- Funds reported $2.32B of Global Blood Therapeutics, Inc. stock for Q4 2018, up 15% quarter-over-quarter.
- 42 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2018 and 33 closed out, a net change of +9 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2018 was Great Point Partners, an estimated $44.2M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2018 was Janus Henderson Group, an estimated $27.9M sold.
Based on aggregated 13F filings for Q4 2018.